Month: October 2020

Recon takes an analytical look behind select developments in healthcare

How does OptumCare manage its physician staffing once the big deals are done?

OptumCare’s acquisitions usually make headlines.  But what happens when the reporters leave? How is clinical capacity managed? What role do micro-acquisitions, recruiting and retirements play in advancing OptumCare capabilities?  This is important because OptumCare is a risk-taking engine.  Perhaps by understanding post-acquisition moves, we can reverse engineer United’s view on how clinician capacity and specialty mix can maximize value.   We looked at two mature OptumCare geographies, Nevada and Texas with large physician presence and healthy United Medicare Advantage market share (just below 50%).  Our analysis primarily uses the Medicare

Read More

A tale of two cities: Referral networks of orthopedic surgeons in Miami and Seattle

Summary: We conducted a comparative analysis of the referral networks of orthopedic surgeons in King County (the area around Seattle, WA) and Miami-Dade County. Similarities Bigger systems are better at keeping referrals internal So, the level of fragmentation in the referral base is associated with the level of fragmentation in the specialty market structure Despite this, a consolidated referral base does not necessarily mean that systems are able to keep orthopedics referrals internal   Miami-Dade Independent physicians make a significant proportion of referrals (9.4%) So, independent surgeons receive a significant

Read More

An ADC renaissance: a resurgence of antibody drug conjugates for cancer

Summary: Antibody-drug conjugates (ADCs) have seen a record number of approvals in 2020. This comes after a first era of intense activity in the early 2000s followed by a period of relative quiescence from the late 2000s to mid-2010s. To understand how the nature of the ADC pipeline has changed over time, we have reviewed all 88 ADC oncology programs that have reached phase 2 development and beyond from 1997 onward. We found that, currently, the main contributor to growth is the development of ADCs which use antibodies directed to

Read More